Kasahara, Shintaro
,
Sakata, Yasuhiko
Nochioka, Kotaro
Yamauchi, Takeshi
Onose, Takeo
Tsuji, Kanako
Abe, Ruri
Oikawa, Takuya
Sato, Masayuki
Aoyanagi, Hajime
Miura, Masanobu
Shiroto, Takashi
Takahashi, Jun
Miyata, Satoshi
Shimokawa, Hiroaki
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (15ek0210043h0001)
Japan Agency for Medical Research and Development (16ek0210056h0001, 16ek0210043h0002)
Article History
Received: 31 October 2017
Accepted: 9 March 2018
First Online: 22 March 2018
Compliance with ethical standards
:
: This study was supported in part by the Grants-in Aid from the Japanese Ministry of Health, Labour, and Welfare and the Japanese Ministry of Education, Culture, Sports, Science, and Technology and the Agency for Medical Research and Development (nos. 15ek0210043h0001, 16ek0210056h0001, 6ek0210043h0002), Tokyo, Japan.
: The Department of Evidence-based Cardiovascular Medicine, Tohoku University Graduate School of Medicine is supported in part by unrestricted research grants from Daiichi Sankyo (Tokyo, Japan), Bayer Yakuhin (Osaka, Japan), Kyowa Hakko Kirin (Tokyo, Japan), Novartis Pharma (Tokyo, Japan), Dainippon Sumitomo Pharma (Osaka, Japan), Astellas Pharma (Tokyo, Japan), AstraZeneca (Osaka, Japan), Chugai Pharmaceutical (Tokyo, Japan), GlaxoSmithKline (Tokyo, Japan), Kowa Pharmaceutical (Tokyo, Japan), Mitsubishi Tanabe Pharma (Osaka, Japan), Mochida Pharmaceutical (Tokyo, Japan), MSD (Tokyo, Japan), Nippon Boehringer Ingelheim (Tokyo, Japan), Otsuka Pharmaceutical (Tokyo, Japan), Shionogi (Osaka, Japan) and Takeda Pharmaceutical (Osaka, Japan). H.S. has received lecture fees from Bayer Yakuhin (Osaka, Japan), Daiichi Sankyo (Tokyo, Japan) and Novartis Pharma (Tokyo, Japan).